The Manufacturers Life Insurance Company Acquires 42,361 Shares of Novo Nordisk A/S $NVO

The Manufacturers Life Insurance Company lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 22.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 229,607 shares of the company’s stock after acquiring an additional 42,361 shares during the period. The Manufacturers Life Insurance Company’s holdings in Novo Nordisk A/S were worth $11,007,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of NVO. Sequoia Financial Advisors LLC lifted its position in Novo Nordisk A/S by 28.8% during the second quarter. Sequoia Financial Advisors LLC now owns 46,177 shares of the company’s stock valued at $2,214,000 after purchasing an additional 10,339 shares in the last quarter. Arlington Capital Management Inc. bought a new stake in Novo Nordisk A/S during the second quarter valued at about $260,000. Archford Capital Strategies LLC purchased a new stake in Novo Nordisk A/S in the second quarter worth about $257,000. NorthRock Partners LLC raised its stake in shares of Novo Nordisk A/S by 78.8% in the second quarter. NorthRock Partners LLC now owns 12,559 shares of the company’s stock worth $602,000 after buying an additional 5,533 shares during the period. Finally, RFG Advisory LLC raised its stake in shares of Novo Nordisk A/S by 49.7% in the second quarter. RFG Advisory LLC now owns 66,135 shares of the company’s stock worth $3,171,000 after buying an additional 21,962 shares during the period. 11.54% of the stock is owned by institutional investors.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy received approval in China for MASH, making it the first GLP-1 receptor agonist in the country approved for the liver disease. The decision expands semaglutide’s potential beyond obesity and diabetes, although Novo has not provided a launch schedule or revenue outlook. Reuters article
• Positive Sentiment: China’s acceptance of Novo’s oral Wegovy application creates a potential avenue into the country’s growing GLP-1 weight-management market. Investors see the opportunity as a possible long-term growth driver, though regulatory approval, launch timing and competitive dynamics remain uncertain. Oral Wegovy China article
• Neutral Sentiment: HSBC raised its price target to 320 Danish kroner but kept a Hold rating, reflecting improved valuation expectations without a strong near-term conviction. HSBC price target article
• Positive Sentiment: Some analysts continue to view Novo’s valuation, strong margins, free cash flow and GLP-1 leadership as providing a margin of safety, suggesting the recent weakness may already reflect substantial execution and competitive risks. Novo Nordisk valuation analysis
• Negative Sentiment: The Morgan Stanley downgrade is the dominant near-term catalyst. Investors are questioning whether oral Wegovy, China expansion and other pipeline opportunities can replace revenue exposed to the semaglutide patent cliff, contributing to NVO’s decline and keeping sentiment weak. Morgan Stanley downgrade article

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $43.03 on Friday. The company has a market capitalization of $192.15 billion, a price-to-earnings ratio of 10.52, a PEG ratio of 1.45 and a beta of 0.74. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The stock’s 50-day simple moving average is $47.49 and its 200-day simple moving average is $43.65. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The firm had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. As a group, analysts expect that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were issued a dividend of $0.5786 per share. This represents a yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 20.05%.

Analysts Set New Price Targets

NVO has been the topic of a number of analyst reports. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Thursday. BMO Capital Markets reiterated a “market perform” rating and issued a $47.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Thursday, August 27th. Four investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and an average target price of $64.94.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.